Top

Published in:

01-08-2013 | Hypertension and the Heart (PW de Leeuw and AH Gradman, Section Editors)

Gender Differences in Hypertension: Myths and Reality

Authors: Michael Doumas, Vasilios Papademetriou, Charles Faselis, Peter Kokkinos

Published in: Current Hypertension Reports | Issue 4/2013

Abstract

Life expectancy is longer in women compared to men, and cardiovascular events occur at a lower rate and at a later age in females than males. The impact of gender on the prevalence, the presentation, and the long-term outcome of cardiovascular disease has long been a topic of active research. Gender differences have been found in several studies but opposite findings also exist. The impact of gender in hypertension and antihypertensive therapy remains poorly clarified. The prevalence, awareness, treatment, and control rates of hypertension exhibit some differences between the two sexes, which are age-dependent. The female advantage in the cardiovascular risk of hypertensive patients might be attenuated by comorbidities and target organ damage. Another aspect of major clinical importance is whether gender differences exist on the effects of antihypertensive agents in blood pressure reduction and cardiovascular morbidity and mortality. The aim of this review is to critically evaluate recent data regarding gender differences in hypertension and incorporate new data into the body of existing knowledge.

Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Chest. 1969;56:43–51.CrossRef

Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care and outcomes. Lancet Neurol. 2008;7:915–26.PubMedCrossRef

Wong C, Froelicher E, Bacchetti P, et al. In a managed care setting, are there sex differences in the use of coronary angiography after acute myocardial infarction? Am Heart J. 1998;135:435–42.PubMedCrossRef

Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation. 2010;3:135–42.PubMed

•• Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e77–86. A very significant annual report showing higher awareness, treatment, and control rates among women compared to men. Control rates were consistently higher in men for decades and this trend was reversed for the first time. CrossRef

Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–50.PubMedCrossRef

Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125:2462–8.PubMedCrossRef

McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci. 2009;64:256–63.PubMedCrossRef

Daugherty SL, Masoudi FA, Ellis JL, et al. Age-dependent gender differences in hypertension management. J Hypertens. 2011;29:1005–11.PubMedCrossRef

10.

Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ. 2012;184:E49–56.PubMedCrossRef

11.

Prince M, Ebrahim S, Acosta D, et al. Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China: a 10/66 cross-sectional population-based survey. J Hypertens. 2011;30:177–87.CrossRef

12.

Gee M, Bienek A, McAlister F, et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol. 2012;28:375–82.PubMedCrossRef

13.

Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286:R233–49.PubMedCrossRef

14.

• Wang L, Szklo M, Folsom A, et al. Endogenous sex hormones, blood pressure change, and risk of hypertension in post-menopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2012;224:228–34. An important study that uncovers the role of sex hormones in blood pressure elevation in post-menopausal women. PubMedCrossRef

15.

Casiglia E, Tikhonoff V, Caffi S, et al. Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. J Hypertens. 2008;26:1983–92.PubMedCrossRef

16.

Carter J, Fu Q, Minson C, Joyner M. Ovarian cycle and sympathoexcitation in premenopausal women. Hypertension. 2013;61:395–9.PubMedCrossRef

17.

Tsuda K. Roles of sex steroid hormones and nitric oxide in the regulation of sympathetic nerve activity in women. Hypertension. 2013;61:e36.PubMedCrossRef

18.

Hart E, Charkoudian N, Wallin B, et al. Sex and ageing differences in resting arterial pressure regulation: the role of b-adrenergic receptors. J Physiol (London). 2011;589:5285–97.CrossRef

19.

Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens. 2011;20:647–53.PubMedCrossRef

20.

•• Schlaich M, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991–6. A very significant proof-of-concept study which highlighted the role of sympathetic nervous system in the pathogenesis of polycystic ovary syndrome. Renal sympathetic denervation not only reduced blood pressure but also improved the severity of the disease itself.PubMedCrossRef

21.

Rands V, Dale M, Kobori H, Prieto M. Sexual dimorphism in urinary angiotensinogen excretion during chronic angiotensin II-salt hypertension. Gend Med. 2012;9:207–18.PubMedCrossRef

22.

Perchere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17:994–1001.CrossRef

23.

Forman J, Stampfer M, Curhan G. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302:401–11.PubMedCrossRef

24.

Kittikulsuth W, Sullivan J, Pollock D. ET-1 actions in the kidney: evidence for sex differences. Br J Pharmacol. 2013;168:318–26.PubMedCrossRef

25.

Kittikulsuth W, Pollock J, Pollock D. Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension. 2011;58:212–8.PubMedCrossRef

26.

Cheng S, Xanthakis V, Sullivan L, Vasan R. Blood pressure tracking over the adult life course. Hypertension. 2012;60:1393–9.PubMedCrossRef

27.

Sangiorgi G, Roversi S, Biondi-Zoccai G, et al. Sex-related differences in carotid plaque features and inflammation. J Vasc Surg. 2013;57:338–44.PubMedCrossRef

28.

Ota H, Reeves M, Zhu D, et al. Sex differences in patients with asymptomatic carotid atherosclerotic plaque. In vivo 3.0-T magnetic resonance study. Stroke. 2010;41:1630–5.PubMedCrossRef

29.

Den Harrog A, Algra A, Moll F, de Borst G. Mechanisms of gender-related outcome differences after carotid endarterectomy. J Vasc Surg. 2010;52:1062–71.CrossRef

30.

Ong K, Tso A, Lam K, Cheung B. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51:1142–8.PubMedCrossRef

31.

Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e59–67.CrossRef

32.

Yanes L, Reckelhoff J. Postmenopausal hypertension. Am J Hypertens. 2011;24:740–9.PubMedCrossRef

33.

Wakabayashi I. Stronger associations of obesity with prehypertension and hypertension in young women than in young men. J Hypertens. 2012;30:1423–9.PubMedCrossRef

34.

Deng WW, Wang J, Liu MM, et al. Body mass index compared with abdominal obesity indicators in relation to prehypertension and hypertension in adults: the CHPSNE study. Am J Hypertens. 2013;26:58–67.PubMedCrossRef

35.

Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e72–6.CrossRef

36.

• Wei G, Coady S, Goff D, et al. Blood pressure and the risk of developing diabetes in African American and Whites. Diabetes Care. 2011;34:873–9. An important analysis of data from three large studies (ARIC, CARDIA, Framingham) revealing that the development of diabetes depends on baseline blood pressure and incident diabetes among hypertensive patients is more frequent in female African-Americans and male Caucasians.PubMedCrossRef

37.

• Stocks T, van Hemelrijck M, Manjer J, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59:802–10. A significant study suggesting that hypertension might be associated with cancer in women but not in men. However, further research is needed in this field before jumping to definite conclusions.PubMedCrossRef

38.

• Cuspidi C, Rescaldani M, Sala C, et al. Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension: an updated review. J Hypertens. 2012;30:2066–73. A valuable meta-analysis showing that left ventricular hypertrophy, as assessed by electrocardiography, is more prevalent in men than in women with hypertension.PubMedCrossRef

39.

Okin P, Gerdts E, Kjeldsen S, et al. Gender difference in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension. 2008;52:100–6.PubMedCrossRef

40.

Piro M, Della Bona R, Abbate A, et al. Sex-related differences in myocardial remodeling. J Am Coll Cardiol. 2010;55:1057–65.PubMedCrossRef

41.

Koster NK, Reddy YM, Schima SM, Almeida NJ. Gender-specific echocardiographic findings in nonagenarians with cardiovascular disease. Am J Cardiol. 2010;105:273–6.PubMedCrossRef

42.

Foll D, Jung B, Schilli E, et al. Magnetic resonance tissue phase mapping of myocardial motion: new insight in age and gender. Circ Cardiovasc Imaging. 2010;3:54–64.PubMedCrossRef

43.

Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006–14.PubMedCrossRef

44.

Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845–54.PubMedCrossRef

45.

Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension. 2011;57:390–6.PubMedCrossRef

46.

Chantler PD, Melenovsky V, Schulman SP, et al. The sex-specific impact of systolic hypertension and systolic blood pressure on arterial-ventricular coupling at rest and during exercise. Am J Physiol. 2008;295:H145–53.

47.

Rossi P, Frances Y, Kingwell BA, Ahimastos AA. Gender differences in artery wall biomechanical properties throughout life. J Hypertens. 2011;29:1023–33.PubMedCrossRef

48.

Shim CY, Park S, Choi D, et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol. 2011;57:1226–33.PubMedCrossRef

49.

Sinning C, Wild P, Echevarria F, et al. Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart study). Am J Cardiol. 2011;107:1841–7.PubMedCrossRef

50.

Neugarten J, Acharaya A, Silbiger S. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319–29.PubMed

51.

Ix J, Chonchol M, Laughlin G, Shlipak M, Whooley M. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul study. Am J Kidney Dis. 2011;58:737–45.PubMedCrossRef

52.

Doublier S, Lupia E, Catanuto P, Elliot S. Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev. 2011;7:28–34.PubMedCrossRef

53.

Mueisan M, Ambrosioni E, Costa F, et al. Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study. J Hypertens. 2012;30:2378–86.CrossRef

54.

Schiller J, Lucas J, Peregoy J. Summary health statistics for US adults: National Health Interview Survey 2010. Vital Health Stat. 2012;252:1–207.

55.

AIHW. Women and heart disease: cardiovascular profile of women in Australia. Report. Cardiovascular disease series no 33. Cat no CVD 49. 2010.

56.

Prince S, Adamo K, Hamel M, et al. A comparison of direct versus self-reported measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act. 2008;5:56–67.PubMedCrossRef

57.

Bursztyn M, Ben-Dov I. Sex differences in salt-sensitivity risk approximated from ambulatory blood pressure monitoring and mortality. J Hypertens. 2013;31:900–5.PubMedCrossRef

58.

Benetos A, Thomas A, Joly L, et al. Pulse pressure amplification, a mechanical biomarker of cardiovascular risk. J Am Coll Cardiol. 2010;55:1032–7.PubMedCrossRef

59.

• Regnault V, Thomas F, Safar M, et al. Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;59:1771–7. An important study proposing pulse pressure amplification as a novel potential predictor of cardiovascular risk.PubMedCrossRef

60.

Rothwell P, Howard S, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.PubMedCrossRef

61.

Rothwell P, Howard S, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.PubMedCrossRef

62.

Schutte R, Thijs L, Liu YP, et al. Within-subject blood pressure level – not variability – predicts fatal and nonfatal outcomes in a general population. Hypertension. 2012;60:1138–47.PubMedCrossRef

63.

Peters R, Wells F, Bulpitt C, Beckett N. Impact of transiently elevated diastolic pressure on cause of death: 29-year follow-up from the General Practice Hypertension Study Group. J Hypertens. 2013;31:71–6.PubMedCrossRef

64.

Pencina M, D’Agostino R, Larson M, Massaro J, Vasan R. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078–84.PubMedCrossRef

65.

Mounier-Vehier C, Simon T, Guedj-Meynier D, et al. Gender-related differences in the management of hypertension by cardiologists: the PARITE study. Arch Cardiovasc Dis. 2012;105:271–80.PubMedCrossRef

66.

Ciambrone G, Kaski J. The importance of gender differences in the diagnosis and management of cardiovascular disease. Curr Pharm Des. 2011;17:1079–81.PubMedCrossRef

67.

• Boggia J, Thijs L, Hansen T, et al. Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension. 2011;57:397–405. This significant clinical study in a large number of patients showed that the preventable cardiovascular risk is significantly higher in women than in men.PubMedCrossRef

68.

Lykke J, Langhoff-Roos J, Sibai B, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944–51.PubMedCrossRef

69.

McDonald S, Malinowski A, Zhou Q, Yusuf S, Devereaux P. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156:918–30.PubMedCrossRef

70.

Bellamy L, Casas J, Hingorani A, Williams D. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974–86.PubMedCrossRef

71.

Mongraw-Chaffin M, Cirillo P, Cohn B. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166–71.PubMedCrossRef

72.

Mosca L, Benjamin E, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–62.PubMedCrossRef

73.

• Schmittdiel J, Selby J, Swain B, et al. Missed opportunities in cardiovascular disease prevention? Low rates of hypertension recognition for women at medicine and obstetrics-gynecology clinics. Hypertension. 2011;57:717–22. This significant report highlights missed opportunities in everyday clinical practice for female cardiovascular risk prevention due to physicians’ lack of familiarity with the future cardiovascular sequelae of preeclampsia.PubMedCrossRef

74.

Basu R, Krueger P, Lairson D, Franzini L. Lifetime medical expenditures among hypertensive men and women in the United States. Women Health Issues. 2011;21:246–53.CrossRef

75.

Franco O, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46:280–6.PubMedCrossRef

76.

Redon J, Olsen M, Cooper R, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32:1424–31.PubMedCrossRef

77.

Martinez-Selles M, Doughty R, Poppe K, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012;14:473–9.PubMedCrossRef

78.

Ford E. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation. 2011;123:1737–44.PubMedCrossRef

79.

Wieberdink R, Ikram M, Hofman A, Koudstaal P, Breteler M. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol. 2012;27:287–95.PubMedCrossRef

80.

Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e109–21.CrossRef

81.

Daugherty S, Masoudi F, Zeng C, et al. Sex differences in cardiovascular outcomes in patients with incident hypertension. J Hypertens. 2013;31:271–7.PubMedCrossRef

82.

Kloner R, Sowers J, DiBona G, et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713–22.PubMedCrossRef

83.

Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. J Clin Hypertens (Greenwich). 2008;10:27–33.

84.

Everett BM, Glynn RJ, Danielson E, Ridker PM. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther. 2008;30:661–72.PubMedCrossRef

85.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRef

86.

Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–8.PubMedCrossRef

87.

b-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707–14.CrossRef

88.

Fletcher A, Beevers DG, Bulpitt C, et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:219–27.PubMed

89.

Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.PubMedCrossRef

90.

Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669–80.PubMedCrossRef

91.

Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51:1149–55.PubMedCrossRef

92.

Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139:476–82.PubMedCrossRef

93.

Lewis CE, Grandits A, Flack J, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med. 1996;156:377–85.PubMedCrossRef

94.

Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51:1103–8.PubMedCrossRef

95.

Mas S, Gasso P, Alvarez S, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics. 2011;21:531–8.PubMedCrossRef

96.

Pemu PI, Ofili E. Hypertension in women—part I. J Clin Hypertens (Greenwich). 2008;10:406–10.CrossRef

97.

Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep. 2012;14:285–92.PubMedCrossRef

98.

Viigimaa M, Doumas M, Vlachopoulos C, et al. Hypertension and sexual dysfunction: time to act. J Hypertens. 2011;29:403–7.PubMedCrossRef

Title: Gender Differences in Hypertension: Myths and Reality
Authors: Michael Doumas
Vasilios Papademetriou
Charles Faselis
Peter Kokkinos
Publication date: 01-08-2013
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 4/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0359-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gender Differences in Hypertension: Myths and Reality

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The Role of Home Blood Pressure Telemonitoring in Managing Hypertensive Populations

Primary Hypertension in Children and Adolescents is an Immuno-Metabolic Disease with Hemodynamic Consequences

The Sympathetic Nervous System in Obesity Hypertension

Role of the Carotid Body in the Pathophysiology of Heart Failure

Dysfunctional Brain-bone Marrow Communication: A Paradigm Shift in the Pathophysiology of Hypertension

Renal Denervation in the Treatment of Hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page